Literature DB >> 21604071

Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy.

Bethany L Mundy-Bosse1, Gregory S Young, Todd Bauer, Elaine Binkley, Mark Bloomston, Matthew A Bill, Tanios Bekaii-Saab, William E Carson, Gregory B Lesinski.   

Abstract

Interferon-alpha (IFN-α) promotes anti-tumor immunity through its actions on immune cells. We hypothesized that elevated percentages of myeloid-derived suppressor cells (MDSC) and increased pro-inflammatory cytokines in peripheral blood would be associated with impaired response to IFN-α in patients with gastrointestinal (GI) malignancies. This study evaluated relationships between plasma IL-6, IL-10, circulating MDSC subsets, and IFN-α-induced signal transduction in 40 patients with GI malignancies. Plasma IL-6 and IL-10 were significantly higher in patients versus normal donors. CD33(+)HLADR(-)CD11b(+)CD15(+) and CD33(+)HLADR(-/low)CD14(+) MDSC subsets were also elevated in patients versus normal donors (P < 0.0001). Plasma IL-6 was correlated with CD33(+)HLADR(-)CD15(+) MDSC (P = 0.008) and IL-10 with CD33(+)HLADR(-)CD15(-) MDSC (P = 0.002). The percentage of CD15(+) and CD15(-) but not CD14(+) MDSC subsets were inversely correlated with IFN-α-induced STAT1 phosphorylation in CD4(+) T cells, while co-culture with in vitro generated MDSC led to reduced IFN-α responsiveness in both PBMC and the CD4(+) subset of T cells from normal donors. Exploratory multivariable Cox proportional hazards models revealed that an increased percentage of the CD33(+)HLADR(-)CD15(-) MDSC subset was associated with reduced overall survival (P = 0.049), while an increased percentage of the CD33(+)HLADR(-/low)CD14(+) subset was associated with greater overall survival (P = 0.033). These data provide evidence for a unique relationship between specific cytokines, MDSC subsets, and IFN-α responsiveness in patients with GI malignancies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21604071      PMCID: PMC3521517          DOI: 10.1007/s00262-011-1029-z

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  50 in total

1.  Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism.

Authors:  Alessandra Mazzoni; Vincenzo Bronte; Alberto Visintin; Jessica H Spitzer; Elisa Apolloni; Paolo Serafini; Paola Zanovello; David M Segal
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

Review 2.  Interferon-alpha as an immunotherapeutic protein.

Authors:  Diana L Brassard; Michael J Grace; Ronald W Bordens
Journal:  J Leukoc Biol       Date:  2002-04       Impact factor: 4.962

Review 3.  Interferons alpha and beta as immune regulators--a new look.

Authors:  C A Biron
Journal:  Immunity       Date:  2001-06       Impact factor: 31.745

4.  Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells.

Authors:  Melissa G Lechner; Daniel J Liebertz; Alan L Epstein
Journal:  J Immunol       Date:  2010-07-19       Impact factor: 5.422

5.  Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies.

Authors:  F De Vita; M Orditura; G Galizia; C Romano; S Infusino; A Auriemma; E Lieto; G Catalano
Journal:  Cancer       Date:  1999-11-15       Impact factor: 6.860

6.  Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation.

Authors:  E M Jaffee; R H Hruban; B Biedrzycki; D Laheru; K Schepers; P R Sauter; M Goemann; J Coleman; L Grochow; R C Donehower; K D Lillemoe; S O'Reilly; R A Abrams; D M Pardoll; J L Cameron; C J Yeo
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

7.  The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse.

Authors:  Gregory B Lesinski; Mirela Anghelina; Jason Zimmerer; Timothy Bakalakos; Brian Badgwell; Robin Parihar; Yan Hu; Brian Becknell; Gerard Abood; Abhik Ray Chaudhury; Cynthia Magro; Joan Durbin; William E Carson
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

8.  Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients.

Authors:  Selma Ugurel; Dario Uhlig; Claudia Pföhler; Wolfgang Tilgen; Dirk Schadendorf; Uwe Reinhold
Journal:  Cancer Immunol Immunother       Date:  2004-01-16       Impact factor: 6.968

9.  Serum interleukin-6 levels reflect the disease status of colorectal cancer.

Authors:  Yuan-Chang Chung; Ya-Fen Chang
Journal:  J Surg Oncol       Date:  2003-08       Impact factor: 3.454

10.  Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients.

Authors:  Amy Morck Thomas; Lynn M Santarsiero; Eric R Lutz; Todd D Armstrong; Yi-Cheng Chen; Lan-Qing Huang; Daniel A Laheru; Michael Goggins; Ralph H Hruban; Elizabeth M Jaffee
Journal:  J Exp Med       Date:  2004-08-02       Impact factor: 14.307

View more
  74 in total

1.  Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells.

Authors:  Gregory B Lesinski; Patrick K Reville; Thomas A Mace; Gregory S Young; Jennifer Ahn-Jarvis; Jennifer Thomas-Ahner; Yael Vodovotz; Zeenath Ameen; Elizabeth Grainger; Kenneth Riedl; Steven Schwartz; Steven K Clinton
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-14

2.  Expansion of myeloid-derived suppressor cells from peripheral blood decreases after 4-week antiviral treatment in patients with chronic hepatitis C.

Authors:  Ying Liu; Lan-Hui She; Xiang-Yang Wang; Geng-Lin Zhang; Ying Yan; Chao-Shuang Lin; Zhi-Xin Zhao; Zhi-Liang Gao
Journal:  Int J Clin Exp Med       Date:  2014-04-15

3.  Vaccine-induced myeloid cell population dampens protective immunity to SIV.

Authors:  Yongjun Sui; Alison Hogg; Yichuan Wang; Blake Frey; Huifeng Yu; Zheng Xia; David Venzon; Katherine McKinnon; Jeremy Smedley; Mercy Gathuka; Dennis Klinman; Brandon F Keele; Sol Langermann; Linda Liu; Genoveffa Franchini; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2014-05-16       Impact factor: 14.808

Review 4.  Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications.

Authors:  C Marcela Diaz-Montero; Jim Finke; Alberto J Montero
Journal:  Semin Oncol       Date:  2014-02-14       Impact factor: 4.929

5.  Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator.

Authors:  Prashant Trikha; Robert L Plews; Andrew Stiff; Shalini Gautam; Vincent Hsu; David Abood; Robert Wesolowski; Ian Landi; Xiaokui Mo; John Phay; Ching-Shih Chen; John Byrd; Michael Caligiuri; Susheela Tridandapani; William Carson
Journal:  Oncoimmunology       Date:  2016-07-25       Impact factor: 8.110

6.  Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCβII abundance.

Authors:  Matthew R Farren; Louise M Carlson; Colleen S Netherby; Inna Lindner; Pui-Kai Li; Dmitry I Gabrilovich; Scott I Abrams; Kelvin P Lee
Journal:  Sci Signal       Date:  2014-02-18       Impact factor: 8.192

Review 7.  Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: A meta-analysis of 40 studies.

Authors:  Peng-Fei Wang; Si-Ying Song; Ting-Jian Wang; Wen-Jun Ji; Shou-Wei Li; Ning Liu; Chang-Xiang Yan
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

8.  Tumor microenvironment and myeloid-derived suppressor cells.

Authors:  Viktor Umansky; Alexandra Sevko
Journal:  Cancer Microenviron       Date:  2012-12-16

9.  The pattern of GPI-80 expression is a useful marker for unusual myeloid maturation in peripheral blood.

Authors:  Y Takeda; T Kato; H Ito; Y Kurota; A Yamagishi; T Sakurai; A Araki; H Nara; N Tsuchiya; H Asao
Journal:  Clin Exp Immunol       Date:  2016-10-04       Impact factor: 4.330

Review 10.  The immunobiology of myeloid-derived suppressor cells in cancer.

Authors:  Morteza Motallebnezhad; Farhad Jadidi-Niaragh; Elmira Safaie Qamsari; Salman Bagheri; Tohid Gharibi; Mehdi Yousefi
Journal:  Tumour Biol       Date:  2015-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.